menu
    • menu

    Find Methazolamide manufacturers, exporters & distributors on PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    9

    API Suppliers

    API Suppliers

    6

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    2

    EU WC

    EU WC

    0

    KDMF

    KDMF

    9

    NDC API

    NDC API

    0

    VMF

    NDC API

    4

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 2,964

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    19

    FDF Dossiers

    FDF Dossiers

    16

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    2

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    1

    USP

    0

    JP

    1

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    14,527,044

    Annual Reports

    NA

    Finished Drug Prices

    NA

    130 RELATED EXCIPIENT COMPANIES

    201EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 554-57-4, Methenamide, Neptazaneat, Neptazane, Naptazane, N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
    Molecular Formula
    C5H8N4O3S2
    Molecular Weight
    236.3  g/mol
    InChI Key
    FLOSMHQXBMRNHR-UHFFFAOYSA-N
    FDA UNII
    DA43GW06P1
    Methazolamide
    A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
    1 2D Structure

    Methazolamide

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
    2.1.2 InChI
    InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
    2.1.3 InChI Key
    FLOSMHQXBMRNHR-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
    2.2 Other Identifiers
    2.2.1 UNII
    DA43GW06P1
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. N Methylacetazolamide

    2. N-methylacetazolamide

    2.3.2 Depositor-Supplied Synonyms

    1. 554-57-4

    2. Methenamide

    3. Neptazaneat

    4. Neptazane

    5. Naptazane

    6. N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide

    7. Chebi:6822

    8. L584601

    9. Methazolamide, (z)-

    10. Nsc-758426

    11. Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)-

    12. Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]-

    13. Mls000028532

    14. Chembl288100

    15. Da43gw06p1

    16. Vvp808

    17. W733b0s9sd

    18. Vvp-808

    19. N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide

    20. Ncgc00016508-01

    21. Metazolamide

    22. Cas-554-57-4

    23. Smr000058287

    24. N-[(2e)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide

    25. L-584601

    26. Metazolamide [dcit]

    27. Metazolamida

    28. Methazolamidum

    29. (ne)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide

    30. Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)-, (n(z))-

    31. Metazolamida [inn-spanish]

    32. Methazolamidum [inn-latin]

    33. 1164547-86-7

    34. Hsdb 3269

    35. Sr-05000001844

    36. Einecs 209-066-7

    37. Brn 0232387

    38. Unii-w733b0s9sd

    39. 2-acetylimino-3-methyl-.delta.(4)-1,3,4-thiadiazoline-5-sulfonamide

    40. 5-acetylimino-4-methyl-.delta.(2)-1,3,4-thiadiazoline-2-sulfonamide

    41. N-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)acetamide

    42. N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide #

    43. Acetamide, N-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)-

    44. (z)-methazolamide

    45. Neptazane (tn)

    46. Methazolamide,(s)

    47. Methazolamide [usp:inn:ban:jan]

    48. Methazolamide, Mza

    49. Prestwick_1007

    50. Methazolamide (mza)

    51. Noname_433

    52. Spectrum_001615

    53. Opera_id_717

    54. Chembl19

    55. Mza3

    56. Prestwick0_000802

    57. Prestwick1_000802

    58. Prestwick2_000802

    59. Prestwick3_000802

    60. Spectrum2_001543

    61. Spectrum3_001914

    62. Spectrum4_000190

    63. Spectrum5_001006

    64. 2-acetylimino-3-methyl-delta(sup 4)-1,3,4-thiadiazoline-5-sulfonamide

    65. 5-acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide

    66. Dsstox_cid_3281

    67. Methazolamide [mi]

    68. Methazolamide [inn]

    69. Methazolamide [jan]

    70. N-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide

    71. Cid_4100

    72. Dsstox_rid_76956

    73. Methazolamide [hsdb]

    74. Unii-da43gw06p1

    75. Dsstox_gsid_23281

    76. Oprea1_161738

    77. Schembl24686

    78. Schembl24687

    79. Bspbio_000663

    80. Bspbio_003508

    81. Kbiogr_000739

    82. Kbioss_002095

    83. Methazolamide [vandf]

    84. 4-27-00-08221 (beilstein Handbook Reference)

    85. Mls001146905

    86. Divk1c_000582

    87. Methazolamide [mart.]

    88. Spectrum1503252

    89. Spbio_001386

    90. Spbio_002584

    91. Methazolamide [usp-rs]

    92. Methazolamide [who-dd]

    93. Bpbio1_000731

    94. Gtpl6828

    95. Methazolamide (jan/usp/inn)

    96. Us10172837, Methazolamide

    97. Chembl1335656

    98. Dtxsid1023281

    99. Schembl13825893

    100. Bdbm10881

    101. Chebi:94513

    102. Hms501n04

    103. Kbio1_000582

    104. Kbio2_002095

    105. Kbio2_004663

    106. Kbio2_007231

    107. Kbio3_003013

    108. Dtxsid50901331

    109. Methazolamide, >=98% (hplc)

    110. Ninds_000582

    111. Bdbm315269

    112. Hms1570b05

    113. Hms1922m19

    114. Hms2093a05

    115. Hms2097b05

    116. Hms2234l03

    117. Hms3259h05

    118. Hms3372g12

    119. Hms3652e21

    120. Hms3714b05

    121. Hms3747o09

    122. Pharmakon1600-01503252

    123. Methazolamide [orange Book]

    124. Hy-b0553

    125. Tox21_110464

    126. Bdbm50013792

    127. Ccg-39321

    128. Methazolamide [usp Monograph]

    129. Mfcd00083416

    130. Nsc758426

    131. Zinc12503151

    132. Akos015897587

    133. Akos024464790

    134. Akos026749792

    135. N-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide

    136. Zinc100019188

    137. Zinc253917094

    138. Ccg-266836

    139. Cl 8490

    140. Db00703

    141. Ks-5328

    142. Nc00618

    143. Nsc 758426

    144. Sb17307

    145. Acetamide, N-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)-

    146. Idi1_000582

    147. N-[(2e)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]acetamide

    148. Ncgc00016508-03

    149. Ncgc00016508-04

    150. Ncgc00016508-18

    151. Ncgc00018188-01

    152. Ncgc00018188-02

    153. Ncgc00018188-03

    154. Ncgc00018188-04

    155. Ncgc00018188-05

    156. Ncgc00018188-06

    157. Ncgc00018188-07

    158. Ncgc00022950-03

    159. Ncgc00022950-04

    160. Ncgc00178022-01

    161. Ncgc00178022-02

    162. Ac-32472

    163. As-13272

    164. Sbi-0051804.p002

    165. Db-052736

    166. A4364

    167. Ab00490015

    168. S4039

    169. Sw197085-3

    170. C07764

    171. D00655

    172. D81966

    173. Ab00052336_04

    174. 554m574

    175. A830656

    176. Methazolamide, Vetranal(tm), Analytical Standard

    177. Q1149099

    178. Sr-05000001844-1

    179. Sr-05000001844-2

    180. Sr-05000001844-3

    181. Brd-k13356952-001-15-2

    182. Brd-k71053238-001-03-6

    183. Brd-k71053238-001-04-4

    184. Q27276292

    185. (e)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene

    186. N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)ethanamide

    187. (nz)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide

    188. Methazolamide, United States Pharmacopeia (usp) Reference Standard

    189. (e)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide

    190. N-(4-methyl-2-sulfamoyl-.delta.(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide

    191. N-[(2z)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide

    192. 2101958-72-7

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 236.3 g/mol
    Molecular Formula C5H8N4O3S2
    XLogP30.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count1
    Exact Mass236.00378248 g/mol
    Monoisotopic Mass236.00378248 g/mol
    Topological Polar Surface Area139 Ų
    Heavy Atom Count14
    Formal Charge0
    Complexity419
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameMethazolamide
    PubMed HealthMethazolamide (By mouth)
    Drug ClassesAntiglaucoma, Cardiovascular Agent
    Drug LabelMethazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone. The chemical name for methazolamide is: N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazo1-2(3H)-ylidene]-acetamide and...
    Active IngredientMethazolamide
    Dosage FormTablet
    RouteOral
    Strength25mg; 50mg
    Market StatusPrescription
    CompanyAni Pharms; Sandoz; Mikart

    2 of 2  
    Drug NameMethazolamide
    PubMed HealthMethazolamide (By mouth)
    Drug ClassesAntiglaucoma, Cardiovascular Agent
    Drug LabelMethazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone. The chemical name for methazolamide is: N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazo1-2(3H)-ylidene]-acetamide and...
    Active IngredientMethazolamide
    Dosage FormTablet
    RouteOral
    Strength25mg; 50mg
    Market StatusPrescription
    CompanyAni Pharms; Sandoz; Mikart

    4.2 Therapeutic Uses

    Carbonic Anhydrase Inhibitors; Diuretics

    National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)

    CARBONIC ANHYDRASE INHIBITOR CHEMICALLY RELATED TO ACETAZOLAMIDE & HAVING SAME PROFILE OF CLINICAL INDICATIONS. ... IT IS INDICATED IN PATIENTS WHO DO NOT RESPOND TO ACETAZOLAMIDE OR IN THOSE WHO ARE INTOLERANT TO IT.

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 867

    ALTHOUGH UNDOUBTEDLY EFFECTIVE IN EVOKING DIURESIS, CARBONIC ANHYDRASE INHIBITORS ARE RELATIVELY INEFFECTIVE COMPARED TO NEWER & MORE EFFICACIOUS AGENTS. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 828

    ACETAZOLAMIDE HAS BEEN GIVEN TO REDUCE INTRAOCULAR PRESSURE IN MGMNT OF GLAUCOMA. IT MAY...BE EMPLOYED FOR ITS ANTICONVULSANT ACTION FOR BOTH GRAND MAL & PARTICULARLY PETIT MAL EPILEPSY. ...ACETAZOLAMIDE APPEARS TO HAVE BENEFICIAL EFFECT IN MGMNT OF PERIODIC PARALYSIS EVEN WHEN ASSOCIATED WITH HYPOKALEMIA. /ACETAZOLAMIDE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 828

    For more Therapeutic Uses (Complete) data for METHAZOLAMIDE (9 total), please visit the HSDB record page.

    4.3 Drug Warning

    CONTRAINDICATIONS, PRECAUTIONS, & ADVERSE REACTIONS ARE SIMILAR TO THOSE OBSERVED WITH ACETAZOLAMIDE & OTHER CARBONIC ANHYDRASE INHIBITORS...

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 867

    SAFE USE OF THESE AGENTS DURING PREGNANCY HAS NOT BEEN ESTABLISHED. THESE AGENTS ARE CONTRAINDICATED IN PATIENTS WITH IDIOPATHIC RENAL HYPERCHLOREMIC ACIDOSIS, RENAL FAILURE, KNOWN DEPLETION OF SODIUM & OF POTASSIUM, ADDISON'S DISEASE, & PATIENTS KNOWN TO BE SENSITIVE TO THIS CLASS OF DRUGS. /CARBONIC ANHYDRASE INHIBITORS/

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 866

    IN EDEMATOUS PATIENT, DAILY ADMIN OF ACETAZOLAMIDE LEADS TO METABOLIC TYPE OF ACIDOSIS THAT IS ACCOMPANIED BY LOSS OF DIURETIC RESPONSE TO CONTINUED DRUG THERAPY. /ACETAZOLAMIDE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826

    CAUTION IS EMPHASIZED IN USE OF CARBONIC ANHYDRASE INHIBITORS IN PATIENTS WITH OBSTRUCTIVE AIRWAY DISEASE.

    PMID:1244265 COUDON WL, BLOCK AJ; CHEST 69 (1): 112-113 (1976)

    For more Drug Warnings (Complete) data for METHAZOLAMIDE (9 total), please visit the HSDB record page.

    4.4 Drug Indication

    For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride.

    5.2 MeSH Pharmacological Classification

    Diuretics

    Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)

    Carbonic Anhydrase Inhibitors

    A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)

    5.3 ATC Code

    S - Sensory organs

    S01 - Ophthalmologicals

    S01E - Antiglaucoma preparations and miotics

    S01EC - Carbonic anhydrase inhibitors

    S01EC05 - Methazolamide

    5.4 Absorption, Distribution and Excretion

    Absorption

    Methazolamide is well absorbed from the gastrointestinal tract.

    Volume of Distribution

    17 to 23 L

    .../CARBONIC ANHYDRASE INHIBITORS/...READILY ABSORBED FROM GI TRACT. PEAK PLASMA CONCN...WITHIN 2 HR. ... EXCRETED BY KIDNEY, BOTH ACTIVE TUBULAR SECRETION & PASSIVE REABSORPTION ARE INVOLVED. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 827

    .../CARBONIC ANHYDRASE INHIBITORS/ ARE TIGHTLY BOUND TO CARBONIC ANHYDRASE &... PRESENT IN GREATER AMT IN THOSE TISSUES IN WHICH ENZYME IS PRESENT IN HIGH CONCN...ERYTHROCYTES & RENAL CORTEX. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 828

    SOME CARBONIC ANHYDRASE INHIBITORS DO NOT PENETRATE ERYTHROCYTE. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 828

    Methazolamide is absorbed more slowly from the GI tract and disappears more slowly from the plasma than does acetazolamide.

    McEvoy, G.K. (ed.). American Hospital Formulary Service-Drug Information 19 98. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1998 (Plus Supplements)., p. 2312

    For more Absorption, Distribution and Excretion (Complete) data for METHAZOLAMIDE (6 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    AZETAZOLAMIDE DOES NOT UNDERGO METABOLIC ALTERATION. .../SOME CARBONIC ANHYDRASE INHIBITORS/ HAVE BEEN FOUND TO BE INACTIVE IN VITRO BUT ACTIVE IN VIVO, AS RESULT OF N-DEALKYLATION TO FORM AN ACTIVE METABOLITE. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 828

    5.6 Biological Half-Life

    14 hours

    Half-life is ~14 hours. /From table/

    Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 693

    5.7 Mechanism of Action

    Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.

    ANTICONVULSANT PROPERTIES...RESEMBLE THOSE OF CARBON DIOXIDE. IN ANIMALS, THEY ABOLISH THE TONIC EXTENSOR COMPONENT OF MAXIMAL ELECTROSHOCK CONVULSIONS, ELEVATE SEIZURE THRESHOLD, & PROTECT AGAINST AUDIOGENIC SEIZURES & THOSE PRODUCED BY WITHDRAWAL FROM HIGH CONCN OF CARBON DIOXIDE. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 218

    MAJOR PHARMACOLOGICAL ACTION...IS INHIBITION OF ENZYME CARBONIC ANHYDRASE. STUDIES WITH PURIFIED ENZYME HAVE SHOWN THAT INHIBITION IS NONCOMPETITIVE. NONCATALYZED HYDRATION OR DEHYDRATION REACTION CAN TAKE PLACE...IN ABSENCE OF ENZYME. /CARBONIC ANHYDRAS INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826

    MORE THAN 99% OF ENZYME ACTIVITY IN THE KIDNEY MUST BE INHIBITED BEFORE PHYSIOLOGICAL EFFECTS BECOME APPARENT. THE ENZYME ITSELF IS DOMINANT TISSUE COMPONENT TO WHICH THE INHIBITORS BECOME BOUND. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826

    FOLLOWING ADMIN OF ACETAZOLAMIDE, THE URINE VOLUME PROMPTLY INCR. NORMALLY ACIDIC PH BECOMES ALKALINE. URINARY CONCN OF BICARBONATE ANION INCR AND IS MATCHED BY SODIUM AND SUBSTANTIAL AMT OF POTASSIUM. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826

    ...THE DRUG HAS BEEN FOUND TO INHIBIT EPILEPTIC SEIZURES & TO DECR RATE OF SPINAL FLUID FORMATION. EXACT MECHANISMS BY WHICH CARBONIC ANHYDRASE INHIBITION IS RELATED TO THESE CHANGES IN FUNCTION ARE NOT CLEAR, & MULTIPLE FACTORS MAY BE INVOLVED. /CARBONIC ANHYDRASE INHIBITORS/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 827

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636482600,"product":"METHAZOLAMIDE USP -FAC INV NO 715200711","address":"NO.27,RACE COURSE ROAD,BANGALORE","city":"KARNATAKA","supplier":"MICRO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"NEW CHIENS BIOTECH ","customerCountry":"TAIWAN","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"3000","totalValueFC":"59271.2","currency":"USD","unitRateINR":220700,"date":"10-Nov-2021","totalValueINR":"4414000","totalValueInUsd":"59271.2","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"5909870","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO.27,RACE COURSE ROAD,BANGALORE, KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677004200,"product":"METHAZOLAMIDE USP ( MTH4P22006 (MFG DATE","address":"NO 31, RACE COURSE ROAD BANGALORE Contact No: 919945641620","city":"BENGALURU","supplier":"MICRO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"CINCINNATI, OH","customer":"LGM PHARMA","customerCountry":"UNITED STATES","quantity":"4.80","actualQuantity":"4.8","unit":"KGS","unitRateFc":"3000","totalValueFC":"14214.8","currency":"USD","unitRateINR":244583.33333333334,"date":"22-Feb-2023","totalValueINR":"1174000","totalValueInUsd":"14214.8","indian_port":"BANGALORE AIR","hs_no":"29359090","bill_no":"7979869","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO 31, RACE COURSE ROAD BANGALORE Contact No: 919945641620, BENGALURU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720549800,"product":"METHAZOLAMIDE USP (CAS NO. 554-57-4)","address":"SHOP NO 30, 1ST FLOOR, SHOPPE LINK","city":"WADALA EAST MUMBAI,MAHARASHTRA","supplier":"VCARE MEDICINES","supplierCountry":"INDIA","foreign_port":"MONTREAL, QC","customer":"TO THE ORDER OF","customerCountry":"CANADA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4500","totalValueFC":"4281","currency":"USD","unitRateINR":357855,"date":"10-Jul-2024","totalValueINR":"357855","totalValueInUsd":"4281","indian_port":"Bombay Air","hs_no":"29359090","bill_no":"2318744","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"SHOP NO 30, 1ST FLOOR, SHOPPE LINK, WADALA EAST MUMBAI,MAHARASHTRA","customerAddress":""}]
    10-Nov-2021
    10-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Methazolamide Manufacturers

    A Methazolamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methazolamide, including repackagers and relabelers. The FDA regulates Methazolamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methazolamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Methazolamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Methazolamide Suppliers

    A Methazolamide supplier is an individual or a company that provides Methazolamide active pharmaceutical ingredient (API) or Methazolamide finished formulations upon request. The Methazolamide suppliers may include Methazolamide API manufacturers, exporters, distributors and traders.

    click here to find a list of Methazolamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Methazolamide USDMF

    A Methazolamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Methazolamide active pharmaceutical ingredient (API) in detail. Different forms of Methazolamide DMFs exist exist since differing nations have different regulations, such as Methazolamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Methazolamide DMF submitted to regulatory agencies in the US is known as a USDMF. Methazolamide USDMF includes data on Methazolamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Methazolamide USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Methazolamide suppliers with USDMF on PharmaCompass.

    Methazolamide WC

    A Methazolamide written confirmation (Methazolamide WC) is an official document issued by a regulatory agency to a Methazolamide manufacturer, verifying that the manufacturing facility of a Methazolamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Methazolamide APIs or Methazolamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Methazolamide WC (written confirmation) as part of the regulatory process.

    click here to find a list of Methazolamide suppliers with Written Confirmation (WC) on PharmaCompass.

    Methazolamide NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Methazolamide as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Methazolamide API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Methazolamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Methazolamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Methazolamide NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Methazolamide suppliers with NDC on PharmaCompass.

    Methazolamide GMP

    Methazolamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Methazolamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methazolamide GMP manufacturer or Methazolamide GMP API supplier for your needs.

    Methazolamide CoA

    A Methazolamide CoA (Certificate of Analysis) is a formal document that attests to Methazolamide's compliance with Methazolamide specifications and serves as a tool for batch-level quality control.

    Methazolamide CoA mostly includes findings from lab analyses of a specific batch. For each Methazolamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Methazolamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Methazolamide EP), Methazolamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methazolamide USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search